RxDoctor Payments Data

Curtis Childress, MD

Otolaryngology · Hattiesburg, MSNPI 1922069921

Payments from drug & device makers

What this record shows

19 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 54.2% of the total. Reporting peaked in 2023 at $1,085 and has fallen 98.1% since, to $20 in 2025.

$1,724in general payments, 2019–2025

Across 43 payments — averaging $40.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$935
  • AbbVie$133
  • Xeris Pharmaceuticals, Inc.$107
  • Novo Nordisk$93
  • Regeneron Healthcare Solutions, Inc.$86
  • Optinose US, Inc.$77
  • plus $294 from 13 others

What the payments were for

  • Travel & lodging$83548%
  • Food & beverage$88952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,724 in reported general payments places this provider in the 60th percentile of 97 otolaryngology providers in Mississippi.

See all otolaryngology providers in Mississippi

Medicare billing

Part B allowed, 2024
$185,837
Medicare patients
554
Services billed
6,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium64$2,906
Dexlansoprazole DrDexlansoprazole12$2,620
Epinephrine13$2,531
Omeprazole175$1,516
Famotidine195$1,427
Ipratropium Bromide45$1,360
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort17$981
Mometasone Furoate34$815
Fluticasone Propionate60$666
Azelastine Hcl17$401
Ofloxacin14$322
Montelukast Sodium34$284
Pantoprazole Sodium13$207
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$130
Prednisone97$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$133$2,90664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 97 otolaryngology providers in Mississippi.

Other otolaryngology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →